Background: Most patients with chronic spontaneous urticaria (CSU) exhibit recurrent angioedema. As of yet, the pathogenesis of angioedema in CSU is largely unclear, especially when angioedema occurs in patients who do not develop wheals. Over the past years, we and others have repeatedly observed that patients with recurrent angioedema alone exhibit impaired glucose tolerance. Aim: To assess blood glucose levels and glucose tolerance in these patients and to compare the results to those of CSU patients who do not develop angioedema. Methods: A total of 29 patients with angioedema alone (15 women, mean age 43.2 ± 12.8 years) and 33 CSU patients (17 women, mean age 41.9 ± 17 years) were investigated and compared for clinical features and laboratory values, including fasting and random blood glucose levels, and glycated hemoglobin (HbA1c%). All patients were subjected to oral glucose tolerance testing (OGTT). Results: Fasting plasma glucose levels, random blood glucose levels and OGTT glucose levels were significantly higher in patients with angioedema alone as compared to CSU patients. Glucose tolerance was impaired in 17 of 29 patients with angioedema alone (58.6%) and only in 2 of 33 CSU patients (6.1%). Patients were found to have an increased risk of high glucose (OR 1.74) and HbA1c (OR 1.83) blood levels and of developing a high BMI (OR 1.97). Conclusion: Recurrent angioedema in patients who do not develop wheals appears to be associated with impaired glucose tolerance and elevated blood glucose levels. We recommend blood glucose measurements in patients with recurrent angioedema alone.

1.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Cannonica GW, et al: Methods report on the development of the 2013 revision and update of the EAACI/GA2LEN/EDF/WHO guideline for the definition, classification, diagnosis and management of urticaria in urticarial. Allergy 2014;69:e1-e29.
2.
Maurer M, Magerl M, Siebenhaar F, Weller K, Krause K: Practical algorithm for diagnosing patients with recurrent wheals or angioedema. Allergy 2013;68:816-819.
3.
Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Cortellini G, Nizankowska- Mogilnicka E, et al: Clinical management of patients with a history of urticarial/angioedema induced by multiple NSAIDs: an expert panel review. Int Arch Allergy Immunol 2013;160:126-133.
4.
Malde B, Regalado J, Greenberger PA: Investigation of angioedema associated with the use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Ann Allergy Asthma Immunol 2007;1:57-63.
5.
Farnam K, Chang C, Teuber S, Gershwin ME: Nonallergic drug hypersensitivity reactions. Int Arch Allergy Immunol 2012;159:327-345.
6.
Agostoni A, Cicardi M: Drug-induced angioedema without urticaria. Drug Saf 2001;24:599-606.
7.
Grigoriadou S, Longhurst HJ: An approach to the patient with angio-oedema. Clin Exp Immunol 2009;155:367-377.
8.
Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ: Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013;161(suppl 1):S3-S9.
9.
Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al: The diagnosis and management of acute and chronic urticarial. J Allergy Clin Immunol 2014;133:1270-1277.
10.
Ye YM, Jin HJ, Nam YH, Kim JH, Shin YS, Park HS: Co-existence of chronic urticarial and metabolic syndrome: clinical implications. Acta Derm Venerol 2013;93:156-160.
11.
Dermatology Life Quality Index (DLQI). www.dermatology.org.uk/quality/dlqi (accessed January 15, 2012).
12.
Kaplan AP: Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002;346:175.
13.
Routh VH: Glucose neurons in the ventromedial hypothalamus. Sensors 2010;10:9002-9025.
14.
Masuzaki H, Tanaka T, Ebihara K, Hosoda K, Nakao K: Hypothalamic melanocortin signaling and leptin resistance-perspective of therapeutic application for obesity-diabetes syndrome. Peptides 2009;30:1383-1386.
15.
Miranda N, Tovar AR, Palacios B, Torres N: AMPK as a cellular energy sensor and its function in the organism. Rev Invest Clin 2007;59:458-469.
16.
Marino JS, Xu Y, Hill JW: Central insulin and leptin-mediated autonomic control of glucose homeostasis. Trends Endocrinol Metab 2011;22:275-285.
17.
Morton GJ: Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007;583:437-443.
18.
Kalra SP, Kalra PS: Subjugation of hypothalamic NPY and cohorts with central leptin gene therapy alleviates dyslipidemia, insulin resistance, and obesity for life-time. EXS 2006;95:157-169.
19.
Maurer M, Bader M, Bas M, Bossi F, Cicardi M, Cugno M, Howarth P, Kaplan A, Kojda G, Leeb-Lunberg F, Lötwall J, Magerl M: New topics in bradykinin research. Allergy 2011;66:1397-1406.
20.
Farkas H: Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 2013;14:571-586.
21.
Sengwee T, Reichman ME, Houston M, Soutworth MR, Ding X, Hernandez AF, Levenson M, Li L, McClockey C, Shoaibi A, Wu E, Zornberg G, Hennessy S: Comparative risk for angioedema associated with the use of drugs that target the Renin-Angiotensin-Aldosterone system. Arch Intern Med 2012;12:1-8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.